We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Analysis Identifies Early-Stage Tumors

By LabMedica International staff writers
Posted on 04 Apr 2017
The development of a blood test that screens for methylated DNA from tumor cells may herald an era of simpler and more precise cancer diagnostics.

Currently there is no existing cell-free DNA (cfDNA)-based method that is able to simultaneously detect cancer and predict its tissue of origin. More...
To fill this gap investigators at the University of California, Los Angeles have proposed a novel method, CancerLocator, which simultaneously infers the proportion and tissue of origin of circulating DNA in a blood sample using genome-wide DNA methylation data.

CancerLocator identifies specific methylation patterns in circulating cancer DNA from different cancer types and compares the patterns to those in a tumor epigenetics database. Since DNA from tumor cells enters the bloodstream in the earliest stages of cancer, this approach offers a method for early detection of the disease.

In a pre-clinical study CancerLocator and two other programs were used to analyze blood samples from 29 liver cancer patients, 12 lung cancer patients, and five breast cancer patients. CancerLocator correctly identified 25 of 29 liver cancer patients and five of 12 lung cancer patients with early stage cancers. Overall CancerLocator had an overall error rate of 0.265 compared to the other two programs, which had rates of 0.646 and 0.604.

Senior author Dr. Xianghong Jasmine Zhou said, "We built a database of epigenetic markers, specifically methylation patterns, which are common across many types of cancer and also specific to cancers originating from specific tissue, such as the lung or liver. We also compiled the same molecular footprint for non-cancerous samples so we had a baseline footprint to compare the cancer samples against. These markers can be used to deconvolute the DNA found freely in the blood into tumor DNA and non-tumor DNA. Non-invasive diagnosis of cancer is important, as it allows the early diagnosis of cancer, and the earlier the cancer is caught the higher chance a patient has of beating the disease. We have developed a computer-driven test that can detect cancer, and also identify the type of cancer, from a single blood sample. The technology is in its infancy and requires further validation, but the potential benefits to patients are huge."

The CancerLocator program was described in the March 24, 2017, online edition of the journal Genome Biology.


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
Gold Member
Hematology Analyzer
Medonic M32B
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.